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The author is the author of The Cost of Abortion (Four Winds 
Publications, LaGrange, GA, 1995) as well as a biotechnology con-
sultant, college instructor, bioethicist, and biomedical researcher. 
He has published research on neuroscience, biomedicine, abortion 
vaccine technology, and the adverse effects of abortion on women. 
I. Introduction 
Is there any surprise at the emotional and political reaction to 
President Bill Clinton's veto of the partial birth abortion bill? No? 
Yet, perhaps what is surprising is the emotional outcry against this 
procedure as compared to the political and social apathy during over 
20 years of abortion (within the United States). Why such a reaction 
from pro-life and Church leaders now; when the same leaders never 
unleashed the same fury and media coverage during the past 23 years 
of abortions? Perhaps the answer will yield clues to the future of 
abortion in the U.S. 
Meanwhile, the availability of abortion clinics and doctors is slow-
ly dwindling. Organized protests at clinics, aoctor's nomes, ami mal-
practice suits against abortion doctors have contributed to the decline 
of abortion service availability. With the decline in available abor-
tion facilities and physicians, how will abortion continue as a method 
of eugenics and population control, as well as an erroneously 
described "reproductive right"? Perhaps the answer lies in the future 
direction of abortion in the U.S. 
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II. Technology Development 
As technological advances in the fields of endocrinology, biotech-
nology, immunology, and pharmacology progress, the creation of new 
abortifacient technologies will continue. Furthermore, these technolo-
gies will target the destruction of life at an ever-earlier stage of devel-
opment. The movement of technologies to destroy life will continue to 
focus at the embryonic (up to 2 months of development) stage. This 
statement is exemplified by the recent Food and Drug Administration 
(FDA) approval of the double-dose birth control pills and FDA market 
approval of RU-486 (Mifepristone). The purpose of the double-dose 
birth control pill is to block uterine implantation of an early stage 
embryo, whereas the progesterone blocking action of RU-486 acts to 
terminate embryonic life up to the first 49 days of development. 
Beyond these recently approved drugs, the development of other 
embryonic stage abortifacients (such as more advanced progesterone 
blockers and ETF) is continuing. Furthermore, the development of an 
abortifacient vaccine is nearly complete. I•2 This technology does not 
block ovulation or conception, but rather blocks embryo implantation 
and lead~ to t:'mbryonic death, '.vhich uppeurs as a menstrual peliud. 
This technology is targeted for world distribution. The vaccines will 
mislead many into believing that they are using a safe, effective form 
of birth control, when in reality, the vaccine will engineer a monthly 
abortion. The vaccines' effects will last for 18 months. 
The early embryo destructive effect on many of these products 
brings us to the next clue to the future of abortion. 
III. Moving Away From Fetal Death 
Advances in technology will reduce the fetal body count while 
vastly increasing the embryonic fatalities. As a consequence, this 
may increase societal acceptance of abortion. How? 
The abortifacient technologies will destroy life at an earlier stage. 
Market studies for RU-4863 alone claim that the product could cap-
ture up to 60% of the clinical surgical abortions in the U.S. Other 
technologies could surpass that figure. 
Furthermore, one method that pro-life uses to convey the humanity 
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or "humanness" of the fetus is to display graphic photos of fetuses 
with well-formed fingers, eyes, hands, toes, a heart beating, etc. 
Advanced abortifacient technologies act to destroy the life in the 
embryonic (e.g. trophoblastic) stage well before toes, eyes, hands, 
etc. , are formed. Also, it will be harder to emotionally associate with 
a "hollow ball of cells" (as in the case of the trophoblastic embryo) 
than with a human-shaped fetus. In essence, the myth that abortion 
just removes a "blob of cells or tissue" will be reinforced. 
Even now, the beginning of life is being redefined at the uterine 
implantation stage (aka nidation), rather than conception. This redef-
inition allows justification for such medical activities as human 
embryo experimentation and the recently publicized incident in 
Britain of the disposal of thousands of human embryos. This redefi-
nition has been supported by the National Institute of Health (NIH) 
and the American Fertility Society (AFS).4.5 
This new redefining of the pre-embryo as not totally human life 
affords not merely research on human embryos, but expanded use of 
abortifacients that destroy early life by killing the pre-embryo or 
blocking uterine implantation (Remember: blocking uterine implan-
tation leads to rapid death of the embryo). At present, some forms 
of birth control (e.g. Intrauterine Devices [IUD] and some versions 
of the birth control pills), already block embryonic implantation into 
the uterus. 
It must be further noted that as more data arises on the complica-
tions due to surgically induced abortions, marketing strategies for 
abortifacient products will capitalize on this data as a motivational 
factor toward more embryo stage-directed abortifacients. Simply 
put, pharmaceutical corporations will use available data on abortion 
complications (e.g. abortion and infertility link; abortion and breast 
cancer link, etc.) to convince the consumer to use birth control that in 
reality is abortifa-cienr-in nature. As the p6pulation of consumers 
accepting this technology increases, total surgical abortions will 
rapidly decrease, while the total number of abortions will rise expo-
nentially. In reality, the population will increasingly be deceived into 
accepting abortifacients as a version of effective birth control. 
The shift from surgical abortions to pharmaceutical abortifacients 
brings us to the next aspect of the future of abortion. 
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IV. Pharmaceutical Abortifacients 
The market shift to pharmaceutical abortifacients has some advan-
tages. First, this technology reduces the role of clinics and doctors. 
Doctors need not use a clinic to prescribe or dispense pharmaceutical 
abortifacients. Rather, doctors may dispense these drugs (or vac-
cines) in their office and such actions will be protected by doctor-
patient confidentiality. Also, as previously noted, increasing dissem-
ination of pharmaceutical abortifacients will lead to a decrease in 
surgical abortions. As surgical abortions decrease, this will reduce 
abortion clinic revenues. Eventually, the declining revenues may 
force many clinics to close. Although some clinics may continue to 
exist by virtue of distributing abortifacient drugs, the most cost eff ec-
tive measure for physicians (and health care providers like HMOs 
and PPOs) will be abortifacient distribution at the physician's office. 
This shift in abortion (from surgical means to pharmaceuticals) 
will further favor the physician in another way. 
One of the strong deterrents for physicians working in the abortions 
industry is malpractice suits. In recent years, a combined force of 
pro-life advocates and legal professionals have unleashed a torrent of 
malpractice suits due to botched abortions. As a result, physician par-
ticipation in the abortion industry has declined as malpractice suits 
and malpractice financial settlements have climbed. As abortifacient 
technology favors pharmaceuticals, the resultant legal/financial 
responsibility shifts away from the sole physician towards the larger 
(and more legally formidable) pharmaceutical corporations. The costs 
of malpractice insurance would be comparably lower (by dispensing 
abortifacients) even though the physician's participation in abortion 
would continue. Malpractice suits would be replaced by drug manu-
facturer law suits which are more lengthy, costly, and more difficult to 
win. Furthermore, recent FDA bias toward RU-486 may require 
future lawsuits against this federal agency. Law suits at this level are 
even more lengthy and difficult (if not impossible) to win. 
The distribution of abortifacients by doctors may make abortion 
more palatable to physicians. One case in point, a 1995 Kaiser 
Family Foundation survey6 has found that doctors who would not 
perform surgical abortions would prescribe the abortifacient drug, 
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RU-486. FurtherIBOre, the same survey demonstrated that a majority 
of the doctors who do not perform abortions have prescribed the 
"morning after pill" for emergency contraception. As more abortifa-
cient products enter the marketplace, physicians (even with their 
knowledge base of endocrinology, pharmacology, and gynecology as 
well as the understanding of the consequences of the use of abortifa-
cient drugs and vaccines) will increasingly tum to prescribe these 
products to terminate early stage pregnancies. 
Finally, as abortifacient pharmaceuticals rise to the predominant 
form of abortion, another important marketing strategy will eventual-
ly influence the future of abortion. 
Recently, Americans have enjoyed the non-prescription availabili-
ty of commonly used pharmaceutical products like Nicorette 1m gum, 
Tagamet™, Zantac™, Rogaine™, and Naproxin (aka Alleve™). The 
process to move a prescription drug to an over the counter drug sta-
tus (commonly referred to as Rx-to-OTC conversions) has been 
accelerating during this decade. Usually, the motivational factor for 
this conversion is the end of the pharmaceutical firm's exclusive 
marketing of this product as its patent expires. 
At present, the only drugs that the FDA will absolutely not allow 
Rx-to-OTC conversions are narcotics. It is conceivable that eventu-
ally some abortifacients pharmaceuticals (as their patent comes up to 
the expiration date) will become available over the counter. Women 
could one day in the near future obtain abortifacients in the discount 
drug stores as easily as purchasing aspirin, antacids, panty hose, or 
nail polish! 
v. Counterstrategies 
With the future of abortion being directed towards pharmaceutical-
ly-based abnrtifa-cients which target-destroying life-earl-y in develGp-
ment, pro-life advocates will face a series of unique challenges. It 
must be noted that along with abortifacient technology develop-
ments, society will increasingly challenge the definition of when life 
begins. For example, some abortifacient vaccine advocates, includ-
ing HCG vaccine (i.e. abortifacient vaccine) researcher Dr. G. F. 
Talwar1, state that life begins not at conception, but when the embryo 
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implants itself into the uterine lining (i.e., nidation). 
As these redefinitions of the genesis of life continue, disguised 
under the cloak of scientific authority, pro-life advocates must 
become scientifically and technologically astute with the technolo-
gies and issues at hand. Sadly, one of the ~ritical weaknesses that 
many major pro-life groups have is a paucity of scientists and tech-
nologically trained staffers proficient in the fields of medicine, phar-
macology, embryology, molecular biology, immunology, biotechnol-
ogy, and biochemistry. Many groups may feebly attempt to occa-
sionally seek out a retired medical advisor, but the true weakness of 
pro-life is their absence of a permanent scientific staff. As some 
groups continue to chant a pro-life mantra, their absence of a staff 
technically aware of the new abortion technologies will only demon-
strate how these groups have been poor stewards of the funds they 
have been entrusted with by their contributors. In short, as the world 
becomes even more complex, pro-life forces must become staffed 
with knowledgeable individuals who can decipher, comprehend, and 
articulate to the general public which technologies promote a culture 
of life and/or a culture of death. To do less, is both financially and 
morally wrong! 
It must be noted that the Alan Guttmacher Institute is the research 
arm of Planned Parenthood. This institute has a PERMANENT staff 
of scientists and researchers who actively conduct research and pub-
lish their work (much of it advocating abortion and contraceptive 
technologies) in peer-reviewed journals, gaining the respect and 
attention of the medical and scientific community as well as the 
American public at large. 
Another weakness within pro-life is the classic conflict between 
being pro-life, but condoning contraception. This is interesting as it 
was contraception that legally heralded abortion (i.e . Roe v 
Wade, 1973) via the Supreme Court decision of GriswoLd V 
Connecticut, (1 965). But, beyond legal considerations, many pro-life 
advocates still remain silent or in a state of neo-denial over the rela-
tionship between contraception and abortion. As contraception 
helped to crystallize the concept of "Babies/children can be a bur-
den" in the American psyche, abortion became the accepted means to 
deal with the "problem". In short, abortion followed as a "solution" 
to the "problem" of pregnancy. 
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Despite medical and pharmaceutical data going back to the 1960s 
demonstrating that certain forms of birth control (e.g. birth control 
pills) did in fact induce a very early stage abortion (example: via 
blocking the implantation of the embryo into the uteririe lining), some 
elements of the pro-life community have remained silent, choosing 
rather to focus on fetal surgical abortions. With this continued schizo-
phrenic mentality, these pro-life elements will become effectively shut 
out (and silenced) in the abortion debate, as the future of abortion pro-
gresses towards pharmaceutical early stage techniques. In essence, as 
the world is being told that the new abortifacients are just "birth con-
trol"; and as the beginning of life is reclassified at nidation, not con-
ception; then the pro-contraception pro-life forces will, by default, 
surrender and become silent in the debate. Meanwhile, more lives 
will be lost amidst the silence over these technologies. 
The counterstrategy to this scenario may require vigorous educa-
tion on two fronts. First, reeducation and active discussion to break 
the myth that life begins some time AFTER conception. Second, dis-
cussion on the real connection between contraception and abortion. 
Finally, a sad but real third possible strategy includes public expo-
sure of the "Fifth Column" pro-life organizations or leaders that qui-
etly accept future abortifacient "contraception". This strategy is 
admittedly painful and publicly unpleasant, but in the future, it may 
be required. As some physicians and therapists have pointed out, 
"The first step to healing the patient is admitting or identifying the 
ailment in question." 
Conclusions 
The future of abortion is a future which will involve technologies 
that destroy life at a much earlier stage of development. As such, it 
will increase public acceptance of a bortion ;reduce the overaH costs 
to pro-abortion facilities; reduce reproductive responsibility; and 
mute much of the societal emotional response to those destroyed in 
the womb. Pro-life will face a plethora of new technologies. These 
technologies will increase the abortion casualty numbers, increase 
abortion access, and reduce the educational opportunities to the gen-
eral public. 
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The response to the future of abortion is two-fold. The challenge 
to pro-life will require the acquisition of scientific and technological 
staffers who can comprehend and educate the public on these tech-
nologies and their consequences. 
Furthermore, a reexamination of the connection between contra-
ception and abortion is required. The strong wall separating these 
two concepts must be pulled down and the public must be thoroughly 
educated on the close ties between abortion and contraception - both 
psychologically and technologically. Those pro-life forces that fail 
to do this may be faced with a future of obsolescence. 
Finally, should pro-life forces fail to warn society about the future 
of abortion and its implications, American society itself may eventu-
ally be faced with obsolescence. 
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